VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.

Slides:

Advertisements

Similar presentations

Meredith Cook Mercer COPHS August,2012. Total Cholesterol HDL Could CVD prediction be improved by also assessing additional lipid-related markers (replacing.

Advertisements

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.

WHITE BLOOD CELL COUNT SECULAR TREND AND MORTALITY: THE BALTIMORE LONGITUDINAL STUDY OF AGING C.Ruggiero; E.J.Metter; A.Cherubini; M.Maggio; R.Sen; S.S.Najjar;

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Cholesterol quintile (mg/dL)

Advances and Controversies in Cardiovascular Risk Prediction Peter Brindle General Practitioner R&D lead Bristol, N.Somerset and S.Glouc PCTs Promises,

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Journal Club Alcohol and Health: Current Evidence July–August 2004.

1 Background Hypertension Type 2 diabetes Coronary heart disease Gallbladder disease Certain cancers Dyslipidemia Stroke Osteoarthritis Sleep apnea Approximately.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

Calcium/Vitamin D-related CV Events Based on Poster 1163 “Risk of Cardiovascular Events with Calcium/Vitamin D – a Re-Analysis of the Women’s Health Initiative”

HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.

Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.

ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.

William B. Kannel, MD, FACC Former Director, Framingham Heart Study

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Gabrielle Sherer Cardiovascular Risk Reduction Jeff Luckring MS, RD.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Controversial Pathophysiologic Contributors to Acute MI and Atherosclerosis Atherothrombotic events occur in individuals without readily apparent risk.

○ South Asians (SAs) have high rates of CHD which are not entirely explained by traditional CVD risk factors. ○ The association of a family history of.

Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

1 Body-Mass Index and Mortality in Korean Men and Women Sun Ha Jee, Ph.D., Jae Woong Sull, Ph.D., Jung yong Park, Ph.D., Sang-Yi Lee, M.D. From the Department.

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

BACKGROUND RESULTS OBJECTIVES METHODS CONCLUSIONS REFERENCES

TNT: Baseline and final LDL cholesterol levels

Teaching Tool: Blood Pressure Classification

ALLHAT Do the SBP differences between the lisinopril and chlorthalidone arms explain the differences in CVD outcomes?

Adjusted mortality risk

The Hypertension in the Very Elderly Trial (HYVET)

A: Epidemiology update

Franklin SS, et al. Circulation 2009;119:243-50

Diabetes Journal Club March 17, 2011

Fung TT, et al. Circulation 2009;119:

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Baseline Characteristics According to Sex

Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.

A.V. Khera et al. N Engl J Med 2011;364:127-35

PROSPER: trial design

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Presentation transcript:

VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count

VBWG Background and objective Margolis KL et al. Arch Intern Med. 2005;165: Background:Increasing evidence supports a role for inflammation in the atherosclerotic process Objective:Describe relationship between baseline leukocyte (WBC) count, future CVD events, and mortality in postmenopausal women Source:Women’s Health Initiative Observational Study

VBWG WHI-OS: Women’s Health Initiative Observational Study Prospective cohort study in 40 US clinical centers 72,242 postmenopausal women age 50–79 yrs, free of CVD and cancer at baseline Main outcome measures: fatal CHD, nonfatal MI, stroke, total mortality Margolis KL et al. Arch Intern Med. 2005;165:500-8.

VBWG Patients Characteristic (N = 72,242) Age (yr)63.1 White (%)83.5 Diabetes (%)4.5 Hypertension (%)34.6 Elevated cholesterol (%)12.8 Current smoker (%)6.1 BMI (kg/m 2 )27.1 WHI-OS: Baseline characteristics Margolis KL et al. Arch Intern Med. 2005;165:500-8.

VBWG WHI-OS: CHD risk according to WBC count quartile P trend = 0.01 Adjusted for all risk factors, including CRP Quartile of WBC count (  10 3 cells/mm 3 ) Q1 2.6– OR Q2 5.0– Q3 6.0– Q4 7.3– P = 0.02 Margolis KL et al. Arch Intern Med. 2005;165:500-8.

VBWG WHI-OS: CHD risk according to CRP quartile Quartile of CRP level (mg/dL) Q1 0.02– OR Q2 0.13– Q3 0.28– Q4 0.60– P = 0.07 P trend = 0.02 Adjusted for all risk factors, including WBC count Margolis KL et al. Arch Intern Med. 2005;165:500-8.

VBWG *P < Bivariate logistic regression model based on joint WBC count  CRP relationship, adjusted for TC/HDL-C ratio WHI-OS: CHD risk in highest WBC count quartile, according to CRP level Quartile of CRP level (mg/dL) Q1 0.02– OR Q2 0.13– Q3 0.28– Q4 0.60– * Margolis KL et al. Arch Intern Med. 2005;165:500-8.

VBWG Clinical implications WBC count >6.7  10 3 cells/mm 3 may identify women at high CVD risk who are not currently identified by traditional CVD risk factors WBC count offers stable, well-standardized, widely available, and inexpensive measure of systemic inflammation Findings add to evidence in men that suggests a similar link; suggest WBC count is predictive independent of CRP Margolis KL et al. Arch Intern Med. 2005;165:500-8.